Monurol Fosfomycin Trometamol Encapsulated Water Soluble Monurol 3g Fosfomycin Trometamol (MONUROL), mono(2-ammonium-2-hydroxy-methyl-1,3-propanediol)(2R-cis)-3-methyloxyranyl)phosphate, is a parent molecule that has a Antibacterial derived from phosphoric acid and developed by Zambon Research Laboratories.
It is dispensed by medical prescription
Fosfomycin trometamol (Monurol) has broad-spectrum bactericidal activity against Gram-positive and Gram-negative microorganisms, including penicillinase-producing strains and bacteria frequently isolated in urinary tract infections (E. coli, Proteus, Klebsiellae, Enterobacter, Pseudomonas, Cocci cluster, etc.).
MONUROL (fosfomycin trometamol) has the following distinctive properties:
- Complete solubility in water
- Fast and effective absorption after oral administration
- High plasma and tissue levels
- The unchanged active compound is excreted mainly through the kidneys
- Elevated bactericidal concentrations are achieved rapidly (in 2-4 hours) and remain for at least 36-48 hours after a single therapeutic dose is administered.
- No cross-resistance to other antibacterials
- Unchanged antibacterial activity under wide variations in urine pH
- Potential synergy with most antibacterials
- Fosfomycin trometamol (Monurol), due to its specific properties, is particularly indicated for short-term prevention (one or two doses) and treatment of
Acute uncomplicated infections of the lower urinary tract. It has been proven that this therapeutic approach guarantees the following advantages:
- It's easy and just as effective as long-term treatment
- Well tolerated
- There is no risk of premature discontinuation of treatment by the patient when clinical symptoms subside; This is a common situation in clinical practice when using long-term treatment for uncomplicated urinary infections.
- Due to its high concentration at the site of infection, it ensures a bactericidal effect on most urinary pathogens, thus reducing the risk of the emergence of new resistant bacterial strains.
